vs

Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.

CF BANKSHARES INC. is the larger business by last-quarter revenue ($15.7M vs $11.2M, roughly 1.4× Verastem, Inc.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs -876.3%, a 916.4% gap on every dollar of revenue.

CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

CFBK vs VSTM — Head-to-Head

Bigger by revenue
CFBK
CFBK
1.4× larger
CFBK
$15.7M
$11.2M
VSTM
Higher net margin
CFBK
CFBK
916.4% more per $
CFBK
40.0%
-876.3%
VSTM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CFBK
CFBK
VSTM
VSTM
Revenue
$15.7M
$11.2M
Net Profit
$5.7M
$-98.5M
Gross Margin
Operating Margin
43.4%
-362.2%
Net Margin
40.0%
-876.3%
Revenue YoY
12.6%
Net Profit YoY
29.9%
-311.1%
EPS (diluted)
$0.88
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CFBK
CFBK
VSTM
VSTM
Q4 25
$15.7M
Q3 25
$15.5M
$11.2M
Q2 25
$15.6M
$2.1M
Q1 25
$14.1M
Q4 24
$14.0M
Q3 24
$13.1M
$0
Q2 24
$12.6M
$10.0M
Q1 24
$12.2M
Net Profit
CFBK
CFBK
VSTM
VSTM
Q4 25
$5.7M
Q3 25
$2.3M
$-98.5M
Q2 25
$5.0M
$-25.9M
Q1 25
$4.4M
Q4 24
$4.4M
Q3 24
$4.2M
$-24.0M
Q2 24
$1.7M
$-8.3M
Q1 24
$3.1M
Operating Margin
CFBK
CFBK
VSTM
VSTM
Q4 25
43.4%
Q3 25
17.5%
-362.2%
Q2 25
41.1%
-2047.9%
Q1 25
39.5%
Q4 24
36.9%
Q3 24
40.4%
Q2 24
15.4%
-182.8%
Q1 24
30.9%
Net Margin
CFBK
CFBK
VSTM
VSTM
Q4 25
40.0%
Q3 25
15.1%
-876.3%
Q2 25
32.3%
-1213.6%
Q1 25
31.4%
Q4 24
35.2%
Q3 24
32.2%
Q2 24
13.5%
-82.6%
Q1 24
25.2%
EPS (diluted)
CFBK
CFBK
VSTM
VSTM
Q4 25
$0.88
Q3 25
$0.36
$-1.35
Q2 25
$0.77
$-0.62
Q1 25
$0.68
Q4 24
$0.68
Q3 24
$0.65
$-0.60
Q2 24
$0.26
$-0.31
Q1 24
$0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CFBK
CFBK
VSTM
VSTM
Cash + ST InvestmentsLiquidity on hand
$259.0M
$137.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$184.4M
$-15.5M
Total Assets
$2.1B
$176.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CFBK
CFBK
VSTM
VSTM
Q4 25
$259.0M
Q3 25
$272.4M
$137.7M
Q2 25
$275.7M
$164.3M
Q1 25
$241.0M
Q4 24
$235.3M
Q3 24
$233.5M
$113.2M
Q2 24
$241.8M
$83.4M
Q1 24
$236.9M
Total Debt
CFBK
CFBK
VSTM
VSTM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$40.5M
Q2 24
$40.3M
Q1 24
Stockholders' Equity
CFBK
CFBK
VSTM
VSTM
Q4 25
$184.4M
Q3 25
$179.3M
$-15.5M
Q2 25
$177.0M
$36.1M
Q1 25
$172.7M
Q4 24
$168.4M
Q3 24
$164.0M
$11.1M
Q2 24
$159.6M
$18.9M
Q1 24
$158.0M
Total Assets
CFBK
CFBK
VSTM
VSTM
Q4 25
$2.1B
Q3 25
$2.1B
$176.9M
Q2 25
$2.1B
$196.3M
Q1 25
$2.1B
Q4 24
$2.1B
Q3 24
$2.1B
$126.4M
Q2 24
$2.0B
$105.7M
Q1 24
$2.0B
Debt / Equity
CFBK
CFBK
VSTM
VSTM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
3.66×
Q2 24
2.14×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CFBK
CFBK
VSTM
VSTM
Operating Cash FlowLast quarter
$18.7M
$-36.2M
Free Cash FlowOCF − Capex
$18.2M
FCF MarginFCF / Revenue
115.6%
Capex IntensityCapex / Revenue
3.1%
Cash ConversionOCF / Net Profit
3.26×
TTM Free Cash FlowTrailing 4 quarters
$33.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CFBK
CFBK
VSTM
VSTM
Q4 25
$18.7M
Q3 25
$5.5M
$-36.2M
Q2 25
$8.0M
$-32.7M
Q1 25
$2.2M
Q4 24
$14.2M
Q3 24
$-1.3M
$-23.8M
Q2 24
$4.0M
$-27.6M
Q1 24
$-1.2M
Free Cash Flow
CFBK
CFBK
VSTM
VSTM
Q4 25
$18.2M
Q3 25
$5.2M
Q2 25
$7.8M
Q1 25
$2.2M
Q4 24
$13.9M
Q3 24
$-1.3M
Q2 24
$4.0M
$-27.6M
Q1 24
$-1.2M
FCF Margin
CFBK
CFBK
VSTM
VSTM
Q4 25
115.6%
Q3 25
33.6%
Q2 25
50.3%
Q1 25
15.2%
Q4 24
99.6%
Q3 24
-9.9%
Q2 24
31.6%
-275.8%
Q1 24
-9.5%
Capex Intensity
CFBK
CFBK
VSTM
VSTM
Q4 25
3.1%
Q3 25
1.7%
Q2 25
0.7%
Q1 25
0.4%
Q4 24
1.9%
Q3 24
0.2%
Q2 24
0.1%
0.1%
Q1 24
0.0%
Cash Conversion
CFBK
CFBK
VSTM
VSTM
Q4 25
3.26×
Q3 25
2.34×
Q2 25
1.58×
Q1 25
0.50×
Q4 24
3.21×
Q3 24
-0.30×
Q2 24
2.35×
Q1 24
-0.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons